Business
Genprex Bolsters Board of Directors, Appoints Three Biotechnology and Healthcare Industry Leaders
Board additions will enhance Company’s ability to execute on key corporate initiatives AUSTIN, Texas--(BUSINESS WIRE)-- Genprex, Inc. (“Genprex” or the
About this update from Genprex, Inc.
[{"type":"text","content":"\nBoard additions will enhance Company’s ability to execute on key corporate initiatives\n\n AUSTIN, Texas--(BUSINESS WIRE)--\nGenprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of three new members to its Board of Directors. The new appointments are designed to strengthen the Company as it executes on its key clinical programs, continues to build its pipeline, and evaluates future license or corporate partnership agreements. The new Board members include Brent Longnecker, Chief Executive Officer of Longnecker & Associates, Jose A. Moreno Toscano, Chief Executive Officer of LFB USA Inc, and William R. (“Will”) Wilson, Jr., Chairman, President and Chief Executive Officer of Wilson Land & Cattle Co.\n\n\nThis strengthening of the Board of Directors closely follows the Company receiving Fast Track Designation from the Food and Drug Administration (FDA) for its lead drug candidate, raising more than $26 million from institutional investors over the last few months, and licensing a new gene therapy drug candidate for diabetes from the University of Pittsburgh. Also, just yesterday, the Company announced that it strengthened its management team by adding two new senior executives, Catherine Vaczy as Executive Vice President and Chief Strategy Officer, and Michael Redman as Executive Vice President and Chief Operating Officer.\n\n\n“We are honored to have Brent, Jose and Will join our Board in what we believe is a transformational time for our Company,” said Rodney Varner, Chief Executive Officer of Genprex. “Their combined experience in regulatory compliance, business development, clinical trial management, and deal structuring will be invaluable as we continue to our develop gene therapy drug candidates and pursue partnerships for our drug candidates. The addition of these outstanding directors, together with our new senior executive hires and a significantly strengthened balance sheet, puts us in an excellent position to execute our plans.”\n\n\nBrent Longnecker has more than 30 years of experience in corporate governance, executive compensation, and risk management consulting for public, private, and non-profit organizations. Mr. Longnecker built one of the country’s ...